ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced positive findings from the company’s EMBRACE phase IIb study.i The ...
Pharmaceutical Technology on MSN3d
Amid deglobalising trade, experts seek AI safeguards for clinical trial supplyThe role of AI in supply chain management proved to be the focal issue at the recent 2025 Clinical Trial Supply Europe ...
Supermicro, Inc. a Total IT Solution Provider for AI/ML, HPC, Cloud, Storage, and 5G/Edge, is introducing a wide range of new systems which are fully optimized for edge and embedded workloads. Several ...
GSK’s ViiV Healthcare has shared clinical data on three potential long-acting HIV treatments, providing a look at how its ...
After a year of controversy and complaints, Sen. Elizabeth Warren is asking a federal watchdog to investigate GSK over its ...
Gilead plans to go straight to Phase III studies for once-yearly lenacapavir, while GSK and Viiv will push forward with their ...
One of the most highly anticipated FDA decisions this month is for Alnylam Pharmaceuticals, which is seeking to expand the ...
as well as other ranitidine products sold by other companies – increased the risk of cancer. GSK has steadfastly denied that Zantac causes cancer, pointing to the lack of any reliable evidence ...
A hearing will get underway in Delaware later today in the latest phase of GSK’s attempts to defend ... as well as other ranitidine products – increased the risk of cancer.
Involves transaction of at least 0.5% of the listed shares of a company. What was Glaxosmithkline Pharmaceuticals Ltd share price previously? Glaxosmithkline Pharmaceuticals Ltd share price was up ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback